Log In
Print this Print this

Onalta (Onalta edotreotide) (formerly OctreoTher)

  Manage Alerts
Collapse Summary General Information
Company Progenics Pharmaceuticals Inc.
DescriptionYttrium-90 radiolabeled somatostatin peptide analog
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationNeuroendocrine tumors
Indication DetailsTreat gastroenteropancreatic neuroendocrine tumor; Treat metastatic carcinoid tumors; Treat metastatic, progressive, somatostatin receptor-positive carcinoid cancer; Treat neuroendocrine tumors
Regulatory Designation EU - Orphan Drug (Treat gastroenteropancreatic neuroendocrine tumor)
PartnerBioMedica Life Sciences S.A.;
Novartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone





Get a free BioCentury trial today